Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

A Comparison of Effectiveness of Oral Sucrolfate, Alginate and Hydrotalcide in Dispeptic Pain Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03635372
Recruitment Status : Completed
First Posted : August 17, 2018
Last Update Posted : August 31, 2018
Information provided by (Responsible Party):
Bulent Erdur, Pamukkale University

Brief Summary:

Dyspepsia is a very common but non-specific complaint that may indicate a group of symptoms that can be attributed to the upper gastrointestinal system, such as epigastric discomfort, abdominal bloating or fullness, stomach upset and nausea or vomiting that may be associated with food.

This study aimed to improve treatment management of patients with complaints of dyspeptic pain and emergency services, and to compare treatment efficacy of oral sucralfate, alginate and hydrotalcite, which are widely used in our country. Literature According to our research, our study is the first study to compare different antacids in our study of emergency serviste dyspepsia.

Condition or disease Intervention/treatment Phase
Dyspepsia Drug: Alginate Drug: Sucralfate Drug: Hydrotalcite Phase 4

Detailed Description:

This study was performed prospectively, randomly, controlled, double-blind to compare the efficacy of oral sucralfate, alginate and hydrotalcite in patients presenting with emergency department dyspeptic complaints at Pamukkale University Medical Faculty Hospital Emergency Medicine Department.

Patients who were referred to the emergency department with stomach ache or dyspeptic complaints were taken to the study. Treatment medicines were applied according to the randomization scheme of the study patients.

This study was carried out in Pamukkale University Faculty of Medicine Emergency Medicine Department during 8 months between 01.03.2016 and 30.10.2016. Approximately 98,000 adult patients / year in the emergency department have a research assistant and / or faculty member who will check the research as a 24-hour primer. This study included 300 cases between 18 and 60 years of age who were admitted to our emergency department with dispeptic complaints, agreed to participate in the study, informed consent, and met inclusion criteria. The criteria for receiving and not receiving work were specified at the beginning of the study.

When appropriate patients were admitted to the study, the patient was taken to the emergency monitoring monitor and monitored once the written consent was obtained. Patients were assigned to one of the study groups according to the study number, according to the randomization scheme prepared by a non-emergency service computer. The numbers for the previously numbered workgroups were kept in unmarked envelopes and the envelope was opened by the study nurse to prepare the study medicine. The study medicines were prepared by an independent person who did not participate in the study or by the responsible work nurse who was at the helpline and was given to the patient by the other nurse. For each group, the drugs prepared in a 10 cc syringe were wrapped around the syringe with a color patch that did not show any similarity. When the medication was given to the patient, the patient's nose was closed and the drug smell was not taken. Patients were observed for 30 minutes in the emergency department and 30-minute VAS (Visual Analog Scale) score 5 and above were given to the patient for rescue treatment.

The information and data of the patients were collected by questionnaire. In the first part of the questionnaire, patients' demographic information address, telephone numbers, medical backgrounds, medications and vital findings were recorded. Detailed physical examinations of all patients were evaluated by emergency physician. Patients diagnosed with dyspepsia other than dyspepsia such as acute coronary syndrome, pancreatitis, cholecystitis, acute abdomen, ileus, malignancy and gastroenteritis were excluded as a result of history and physical examination. Patients who did not give their consent to participate were also excluded from the study. The patient with unexplained dyspepsia was directed to the gastroenterology polyclinic for endoscopy with necessary information. After discharge, patients were asked whether they had recurring epigastric pain within 24 hours.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Comparison of Effectiveness of Oral Sucrolfate, Alginate and Hydrotalcide in Dispeptic Pain Treatment: Randomized Trial
Actual Study Start Date : June 20, 2017
Actual Primary Completion Date : October 22, 2017
Actual Study Completion Date : November 25, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Indigestion
Drug Information available for: Sucralfate

Arm Intervention/treatment
Experimental: Alginate
10 cc of Alginate peroral
Drug: Alginate
10 cc of Alginate peroral
Other Name: Gaviscon Lipuid

Experimental: Sucralfate
10 cc of Sucralfate peroral
Drug: Sucralfate
10 cc of Sucralfate peroral
Other Name: Antepsin Suspension

Experimental: Hydrotalcite
10 cc of Hydrotalcite peroral
Drug: Hydrotalcite
10 cc of Hydrotalcite peroral
Other Name: Talcid Suspension

Primary Outcome Measures :
  1. Relief of Gastric Pain [ Time Frame: Change from baseline in dispeptic complaint VAS scores at 60 minutes ]
    Compare relief of dispeptic complaint with using VAS (Visual Analog Scale) in 3 groups of alginate, sucralfate and hydrotalcite patients. Patients' pain scores were recorded using 0-100 mm VAS (Visual Analog Scale) to score the degree of dyspeptic complaints. VAS; It is composed of a measured horizontal or vertical line and often carries definitions of "no symptoms" on one end and "severe symptoms" on the other end. The patient is told to mark a point on the line according to the severity of the symptom. The location of the marker allows the severity of the symptom to be measured. The VAS markings on the evaluation forms prepared for the study before and during the procedure were made by the patient himself and regardless of the previous sign. Patients with VAS> 50 were treated. Patients were observed for 60 minutes in the emergency department and 60-minute VAS (Visual Analog Scale) score above 50 were given to the patient for rescue treatment.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Stomach pain, swelling or dispeptic complaints.
  • Men and women between the ages of 18-60.
  • Patients with VAS> 5.

Exclusion Criteria:

  • Pregnancy and lactation.
  • Sucralfate, alginate, hydrotalcite allergy.
  • Emergency service arrives with acute psychiatric symptoms.
  • Gastrointestinal system bleedings.
  • Chronic renal failure, liver cirrhosis, structural and functional heart disease.
  • Gastric malignancy and terminal illness.
  • Patients suspected of having a different problem such as ileus, biliary colic,
  • pancreatitis, hepatitis.
  • Patients who refuse to participate in the study.
  • Those who can not use VAS.
  • Presence of ischemic findings on the arrival ECG.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03635372

Layout table for location information
Pamukkale University
Denizli, Turkey, 20070
Sponsors and Collaborators
Pamukkale University
Layout table for investigator information
Principal Investigator: Gulgun Battal, MD Pamukkale University

Layout table for additonal information
Responsible Party: Bulent Erdur, professor, Pamukkale University Identifier: NCT03635372    
Other Study ID Numbers: 2016TPF001
First Posted: August 17, 2018    Key Record Dates
Last Update Posted: August 31, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Bulent Erdur, Pamukkale University:
Emergency Department
Viscous Lidocaine
Additional relevant MeSH terms:
Layout table for MeSH terms
Signs and Symptoms, Digestive
Signs and Symptoms
Aluminum Hydroxide
Magnesium Hydroxide
Anti-Ulcer Agents
Gastrointestinal Agents
Molecular Mechanisms of Pharmacological Action
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs